BioSpace News Archive

MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail”) a technology-enabled pharmacy company, today reported financial results for the three months and full year ended December 31, 2020.

INVO Bioscience, Inc. (Nasdaq: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System, today announced financial results for the year ended December 31, 2020.

LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced that chief executive officer Frederic Chereau will be participating on a panel at the 2021 Redburn Gene Therapy Summit.

RELIEF THERAPEUTICS today announced the release of 60-day results from the phase 2b/3 trial of intravenously administered RLF-100(TM) by its partner NeuroRx, Inc.

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that it has commenced a proposed underwritten public offering of shares of its common stock. In connection with this offering, 9 Meters Biopharma expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock to be sold in the offering.

Invacare Corporation (NYSE:IVC)(the “Company”), a leading manufacturer and distributor of medical equipment used in non-acute care settings, announced that Matt Monaghan, chairman, president and chief executive officer will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021 at 2:15 p.m. ET

Two novel vaccine candidates for the prevention and treatment of genital herpes have shown to be safe in pre-clinical animal studies according to a study published in the journal Vaccines.

Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has acquired Bioness, Inc . (“Bioness”), a global leader in neuromodulation and rehabilitation medical devices through its innovative peripheral nerve stimulation (“PNS”) therapy and premium rehabilitation solutions, for $45 million in up-front consideration, with up to $65 million of contingent consideration

AmerisourceBergen Corporation (NYSE: ABC) today announced the closing of its public offering of $1,525,000,000 aggregate principal amount of its 0.737% Senior Notes due March 15, 2023 (the “2023 Notes”) and $1,000,000,000 aggregate principal amount of its 2.700% Senior Notes due March 15, 2031 (the “2031 Notes” and, together with the 2023 Notes, the “Notes”), in an underwritten registered public offering.

Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces today that it has completed an agreement with contract development and manufacturing organisation (CDMO) Grand River Aseptic Manufacturing (‘GRAM’) to perform commercial-scale Good Manufacturing Practice (GMP) manufacturing of Telix’s Illuccix ® product (TLX591-CDx, Kit for the preparation of 68 Ga-PSMA-11) for prostate cancer imaging.